Rashmi Jain, MD
Nephrology · Burlingame, CANPI 1346444577
Payments from drug & device makers
Across 132 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$632
- Bayer$449
- AstraZeneca$412
- OPKO Pharmaceuticals, LLC$242
- Fresenius USA Marketing, Inc.$228
- Calliditas Therapeutics US Inc.$215
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,01792%
- Education$2478%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $632 |
| Bayer | 14 | $449 |
| AstraZeneca | 15 | $412 |
| OPKO Pharmaceuticals, LLC | 17 | $242 |
| Fresenius USA Marketing, Inc. | 12 | $228 |
| Calliditas Therapeutics US Inc. | 9 | $215 |
| Lilly USA, LLC | 6 | $142 |
| Bard Peripheral Vascular, Inc. | 1 | $139 |
| Boston Scientific | 1 | $129 |
| Novo Nordisk | 7 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| GSK | 3 | $64 |
| Akebia Therapeutics Inc | 3 | $60 |
| Abbott | 3 | $57 |
| Arbor Pharmaceuticals, Inc. | 3 | $52 |
| Travere Therapeutics, Inc. | 1 | $30 |
| Insmed, Inc. | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,263 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 60 | $167,522 |
| KerendiaFinerenone | 82 | $102,755 |
| FarxigaDapagliflozin Propanediol | 58 | $64,872 |
| JardianceEmpagliflozin | 43 | $59,688 |
| JanuviaSitagliptin Phosphate | 37 | $52,533 |
| OzempicSemaglutide | 43 | $46,093 |
| TrulicityDulaglutide | 24 | $42,106 |
| EliquisApixaban | 42 | $37,257 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $33,252 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $27,879 |
| RybelsusSemaglutide | 14 | $26,018 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 129 | $23,544 |
| Cinacalcet Hcl | 60 | $22,577 |
| Sevelamer Carbonate | 28 | $8,811 |
| Paricalcitol | 17 | $6,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $242 | $167,52260 claims |
| BayerKerendia | $449 | $102,75582 claims |
| AstraZenecaFarxiga, Lokelma | $412 | $92,75173 claims |
| Novo NordiskOzempic, Rybelsus | $125 | $72,11157 claims |
| Lilly USA, LLCTrulicity | $142 | $42,10624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.
Other nephrology in Burlingame
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.